Diphoorn J, Cazzaniga S, Gamba C et al (2016) Incidence, causative factors and mortality rates of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf 25:196–203

Article  CAS  PubMed  Google Scholar 

Osa A, Uenami T, Koyama S et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3:e59125

Article  PubMed  PubMed Central  Google Scholar 

Saad E, Adhikari P, Antala D et al (2022) Steven-Johnson syndrome: a rare but serious adverse event of Nivolumab use in a patient with metastatic gastric adenocarcinoma. J Med Cases 13:449–455

Article  PubMed  PubMed Central  Google Scholar 

Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506–1517

Article  CAS  PubMed  Google Scholar 

Karthikeyan K, Sameera KV, Shaji S et al (2022) Capecitabine induced Steven-Johnson syndrome: a rare case report. J Oncol Pharm Pract 28:250–254

Article  PubMed  Google Scholar 

Dine J, Gordon R, Shames Y et al (2017) Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs 4:127–135

Article  PubMed  PubMed Central  Google Scholar 

Komo T, Suzuki T, Tazawa H et al (2021) Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: a case report. Int J Surg Case Rep 84:106161

Article  PubMed  PubMed Central  Google Scholar 

Takagi T, Yoshida K, Kobayashi H et al (2018) Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 48:860–863

Article  PubMed  Google Scholar 

Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang C, Thudium KB, Han M et al (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846–856

Article  CAS  PubMed  Google Scholar 

Yamamoto N, Nokihara H, Yamada Y et al (2017) Phase I study of nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs 35:207–216

Article  CAS  PubMed  Google Scholar 

Zimmerman D, Dang NH (2019) Stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions. Oncol Critical Care 9:267–280

Google Scholar 

Maloney NJ, Ravi V, Cheng K et al (2020) Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 59:e183–e188

Article  PubMed  Google Scholar 

Coleman E, Ko C, Dai F et al (2019) Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 80:990–997

Article  CAS  PubMed  Google Scholar 

Kumar R, Das A, Das S (2018) Management of stevens-johnson syndrome-toxic epidermal necrolysis looking beyond guidelines! Indian J Dermatol 63:117–124

PubMed  PubMed Central  Google Scholar